Webinars and Sponsored Roundtables — Register Now
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Beckman Coulter
| Company | Beckman Coulter |
|---|---|
| Name of analyzer | DxH 520 Hematology Analyzer |
| Contact | Eric Pabon |
| City, State | Brea, CA |
| Phone | 714-993-5321 |
| Website | 714-993-5321 http://www.beckmancoulter.com |
| Analyzer application | diagnostic and research use |
| Dimensions of analyzer (H × W × | 16 × 10.6 × 16.9 in./5.02 sq. ft. |
| Country where analyzer was | U.S./U.S. |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2019/1, 250 |
| First year analyzer sold outside | 2019/>2, 015 |
| Foreign locations where company | worldwide (installed worldwide) |
| Human languages (other than | Japanese, Chinese, French, Italian, German, Spanish, Portuguese, Danish, Swedish, Greek, Czech, others |
| Analyzer list price | $40, 000 |
| • Analyzer acquisition options | purchase, lease |
| Training included with purchase/Total time for basic training per operator | 30 min. daily |
| • Follow-up training available | yes (extra charge) |
| Parameters that analyzer tests and reports | %&# eosinophils, %&# lymphocytes, %&# monocytes, %&# neutrophils, %&# basophils, Hb, Hct, MCH, MCHC, MCV, PLT, RBC, WBC |
| Types of testing FDA cleared or approved for analyzer | blood count analysis |
| Types of body fluids FDA cleared or approved for analysis on analyzer | — |
| Analytical measurement range for body fluid | — |
| Precision for body fluid | — |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | no |
| Tests available for research use only | low hemoglobin density, microcytic anemia factor, more |
| Differential methods used | CBC analysis based on Coulter Principle; uses simultaneous measurements of volume, axial light loss within WBC aperture to count and size lymphocytes, monocytes, neutrophils, eosinophils, basophils |
| Analytical measurement range: • WBC count/RBC count | WBC: 0.20–100.00 × 103 cells/μL/RBC: 0.20–8.00 × 106 cells/μL |
| Precision: • WBC count/RBC count | WBC: 0.20 to <1.00 × 103 cells/μL: ≤0.15 SD; 1.00 to 5.00–7.00 × 103 cells/μL: ≤4.00% CV; >7.00–100.00 × 103 cells/μL: ≤3.00% CV/RBC: 1.00–3.50 × 106 cells/μL: ≤3.00% CV; 3.50–8.00 × 106 cells/μL: ≤2.00% CV |
| Accuracy: • WBC count/RBC count | WBC: 0.20–100.00 × 103 cells/μL/RBC: 0.20–8.00 × 106 cells/μL |
| Interfering substances: • WBC/RBC | unlysed RBCs, NRBCs, cryoglobulin, cryofibrinogen, platelet clumps, giant platelets, agglutinated WBCs/agglutinated RBCs, unlysed RBCs, elevated WBCs, more |
| • Hemoglobin/Platelets | lipids >62.5 mg/dL (lipemia)/giant platelets, platelet clumps, microcytic RBCs, cryoglobulin, WBC or RBC fragments |
| • Hematocrit/Reticulocytes | agglutinated RBCs, unlysed RBCs, elevated WBCs, more/— |
| • Automated differential | unlysed RBCs, NRBCs, cryoglobulin, cryofibrinogen, platelet clumps, giant platelets, agglutinated WBCs |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | 60 open vial, 55 closed vial/60 open vial, 55 closed vial |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | none |
| Min. specimen volume open mode/Closed mode/Microsample capability | 16.7 μL/16.7 μL/yes |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | results, flags, demographics/30, 000 |
| Analyzer performs delta checks | yes |
| Parameters for which flags may appear | flagging limits, system messages, editing of parameters |
| Analyzer recognizes and holds test results | yes, for follow-up, confirmatory testing, and potential test rerun (parameters for flags to hold samples defined by client or vendor) |
| Scattergram display uses cell-specific color | yes |
| Histogram display uses color with thresholds | yes |
| LIS interface formats supported | proprietary (analyzer or vendor specific), ASTM 1394-91, ASTM 1238-95, IEEE MIB |
| • Middleware interface | no (connects directly to LIS) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results, histograms, scatterplots, patient demographics, patient orders |
| Analyzer transmits LOINC codes for results to LIS or middleware | yes (also provides list of machine codes for each test and corresponding LOINC code) |
| Lab automation system or workcells to which analyzer has a direct interface | none |
| Barcode symbologies read on specimen tube | Codabar, Code 39, Code 128, Interleaved 2 of 5 |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | no |
| No. of onboard reagents required for standard specimen analysis | 3 |
| • Reagents ready to use/Reagent tracking method | yes/barcode reader |
| Onboard diagnostics for troubleshooting | no |
| • Manufacturer can perform diagnostics via remote access | no |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/variable |
| Notes | †also marketed by Medline, McKesson, Henry Schein, Thermo Fisher Scientific |